Takaaki Terahara, PhD

  • 2Articles
  • 13.9KReads1
  • 2020–2022Active
  • 10Collaborators
  • 26Citations2

About

Takaaki Terahara, PhD, is affiliated with Hisamitsu Pharmaceutical Co, Inc. in Chiyoda-ku, Tokyo, Japan. Terahara has published research focused on the treatment of schizophrenia and schizoaffective disorders, specifically investigating the efficacy and safety of HP-3070, an asenapine transdermal system. The work includes analyses of symptom management and clinical trial data from phase 3 studies. Collaborators frequently include Leslie Citrome, Marina Komaroff, and Alexandra S. Park.

Publications

JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

Transdermal HP-3070 for Hostility in Schizophrenia

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Original Research

Asenapine Transdermal System for Schizophrenia

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe